Taken together, these studies demonstrate that the activation of FOXOs has significant implication for the treatment and prevention of pancreatic cancer, where Kras is activated in about 90% patients, and PI3K/AKT and MEK/ERK pathways are highly activated. The gene discussed is AKT1; the disease is familial pancreatic carcinoma.